(Q44203355)

30 November 2017

title

Effect of highly purified urinary follicle-stimulating hormone on oocyte and embryo quality (English)

1 reference

30 November 2017

Helmy A Selman

1

1 reference

30 November 2017

Mariella De Santo

2

1 reference

30 November 2017

Karl Sterzik

3

1 reference

30 November 2017

Elisabetta Coccia

4

1 reference

30 November 2017

Imam El-Danasouri

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

30 November 2017

published in

Fertility and Sterility

1 reference

30 November 2017

volume

78

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

1061-1067

1 reference

Reducing the Risk of Multiple Births by Transfer of Two Embryos after in Vitro Fertilization

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Delayed-type hypersensitivity to human gonadotropin: case report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotrophin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Oocyte assessment and biological performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Controlled ovarian stimulation using highly purified FSH results in a lower serum oestradiol profile in the follicular phase as compared with HMG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Clinical experience with recombinant follicle-stimulating hormone (FSH) and urinary FSH: a retrospective case- controlled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A prospective, randomized, controlled clinical study of a new subcutaneous, purified, urinary FSH preparation for controlled ovarian hyperstimulation in in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Biological characterization of recombinant human follicle stimulating hormone isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

The role of luteinizing hormone in folliculogenesis and ovulation induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904202-4

10.1016/S0015-0282(02)04202-4

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference